Practitioner's Docket No.: 701826-051150

IN THE UNITED STATES RECEIVING OFFICE (RO/US)

#	5	
	BO	اء
ĺ	10-16	101

	17 June 1999	17 June 1998
09/719,737 Application No.	International Filing Date	Priority Date Claimed
ANTISENSE OLIGO ATOPIC DISEASES	NUCLEOTIDESFOR TREATING OR P AND NEOPLASTIC CELL PROLIFERA	REVENTING TION
Title		
<u>Paolo Renzi, et al.</u> Applicants		
Thhuenne		

CERTIFICATE OF MAILING

I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. <u>EL565098855US</u> in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231.

Date: September 26, 2001

Nicole M. Gignac

Box PCT Assistant Commissioner for Patents Washington, D.C. 20231

Attention: EO/US

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, BA – BM and CA, cited in the attached Form PTO-1449.

In re application of: Renzi, P., et al. Application No.: 09/719,737 Int. Filing Date:

17 June 1999

17 June 1998

Priority Date: For:

ANTISENSE OLIGONUCLEOTIDES FOR TREATING OR PREVENTING ATOPIC DISEASES

Examiner: Not yet assigned

Group Art: Not yet assigned

AND NEOPLASTIC CELL PROLIFERATION

REMARKS

In accordar	nce with th	ne provisions of 37 C.F.R. §1.97, this statement is being filed:	
_X	(1)	within three (3) months of the Filing Date or before the mailing date of	
		the First Office Action on the merits in the CPA application; or	
	(2)	within three months of the mailing date of the PCT International Search	
		Report; or	
	(3)	after the period defined in (1) but before the mailing date of a Final	
		Rejection or Notice of Allowance, and the requisite Certification or fee	
		under Rule 1.17(p), namely \$240.00, is included herein; or	
	(4)	after the mailing date of a Final Rejection or Notice of Allowance but	
		before the payment of the Issue Fee, and the requisite Certification,	
		petition, and petition fee are included herein.	
	A co	py of the International Search Report is enclosed herewith.	
It i	s respectf	ully requested that each of the documents shown on the attached form(s)	
PTO-1449	be made	of record in this application. Copies of these documents (CHECK ONE):	
<u>X</u>	are e	are enclosed herewith.	
	have	been cited in the parent application, and are thus not being resubmitted	
	herei	in.	

In re application of: Renzi, P., et al. Application No.: 09/719,737

17 June 1999

Priority Date:

Int. Filing Date:

17 June 1998

For:

ANTISENSE OLIGONUCLEOTIDES FOR TREATING OR PREVENTING ATOPIC DISEASES

Examiner: Not yet assigned

Group Art: Not yet assigned

AND NEOPLASTIC CELL PROLIFERATION

FEE AUTHORIZATION

Should any fees associated with the submission be required, the Commissioner is authorized to charge the missing fee to our Deposit Account No. 50-0850. Any overpayments should be credited to said Deposit Account.

Date: September 26, 2001

Customer No.: 26770

Respectfully submitted,

David S. Resnick (Reg. No. 34,235) Lana A. Shvartsman (Reg. No. 48,502)

NIXON PEABODY LLP

101 Federal Street Boston, MA 02110 Tel.: (617) 345-6057